PIK3CG

Oncogene
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform UniProt accession P48736

Phosphoinositide-3-kinase (PI3K) that phosphorylates PtdIns(4,5)P2 (Phosphatidylinositol 4,5-bisphosphate) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3 plays a key role by recruiting PH domain-containing proteins to the membrane, including AKT1 and PDPK1, activating signaling cascades involved in cell growth, survival, proliferation, motility and morphology. Links G-protein coupled receptor activation to PIP3 production.

Involved in immune, inflammatory and allergic responses. Modulates leukocyte chemotaxis to inflammatory sites and in response to chemoattractant agents. May control leukocyte polarization and migration by regulating the spatial accumulation of PIP3 and by regulating the organization of F-actin formation and integrin-based adhesion at the leading edge.

Controls motility of dendritic cells. Together with PIK3CD is involved in natural killer (NK) cell development and migration towards the sites of inflammation. Participates in T-lymphocyte migration.

Regulates T-lymphocyte proliferation, activation, and cytokine production. Together with PIK3CD participates in T-lymphocyte development. Required for B-lymphocyte development and signaling.

Together with PIK3CD participates in neutrophil respiratory burst. Together with PIK3CD is involved in neutrophil chemotaxis and extravasation. Together with PIK3CB promotes platelet aggregation and thrombosis.

Regulates alpha-IIb/beta-3 integrins (ITGA2B/ ITGB3) adhesive function in platelets downstream of P2Y12 through a lipid kinase activity-independent mechanism. May have also a lipid kinase activity-dependent function in platelet aggregation. Involved in endothelial progenitor cell migration.

Negative regulator of cardiac contractility. Modulates cardiac contractility by anchoring protein kinase A (PKA) and PDE3B activation, reducing cAMP levels. Regulates cardiac contractility also by promoting beta-adrenergic receptor internalization by binding to GRK2 and by non-muscle tropomyosin phosphorylation.

Also has serine/threonine protein kinase activity: both lipid and protein kinase activities are required for beta-adrenergic receptor endocytosis. May also have a scaffolding role in modulating cardiac contractility. Contributes to cardiac hypertrophy under pathological stress.

Through simultaneous binding of PDE3B to RAPGEF3 and PIK3R6 is assembled in a signaling complex in which the PI3K gamma complex is activated by RAPGEF3 and which is involved in angiogenesis. In neutrophils, participates in a phospholipase C-activating N-formyl peptide-activated GPCR (G protein-coupled receptor) signaling pathway downstream of RASGRP4-mediated Ras-activation, to promote neutrophil functional responses (By similarity)

Source: UniProt

Heterodimer of a catalytic subunit PIK3CG and a PIK3R5 or PIK3R6 regulatory subunit. Interacts with GRK2 through the PIK helical domain. Interaction with GRK2 is required for targeting to agonist-occupied receptor.

Interacts with PDE3B; regulates PDE3B activity and thereby cAMP levels in cells (By similarity). Interacts with TPM2. Interacts with EPHA8; regulates integrin-mediated cell adhesion to substrate.

Interacts with HRAS; the interaction is required for membrane recruitment and beta-gamma G protein dimer-dependent activation of the PI3K gamma complex PIK3CG:PIK3R6 (By similarity)

Source: UniProt
Cytoplasm, Cell membrane
Source: UniProt

Pancreas, skeletal muscle, liver and heart

Source: UniProt
  • Immunodeficiency 97 with autoinflammation (IMD97)

    An autosomal recessive disorder with variable features. Affected individuals have childhood-onset antibody defects, cytopenias, and T lymphocytic pneumonitis and colitis. Some patients may have features of hemophagocytic lymphohistiocytosis.

Source: UniProt
  • GPVI-mediated activation cascade
  • PIP3 activates AKT signaling
  • Synthesis of PIPs at the plasma membrane
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • CD28 dependent PI3K/Akt signaling
  • G beta:gamma signalling through PI3Kgamma
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Co-stimulation by ICOS
Source: Reactome via UniProt

Mutations

Cancer Type Mutation Percentage
Central Nervous System Astrocytoma Grade Iv 2.28%
Lung Adenocarcinoma 5.32%
Lung Small Cell Carcinoma 2.67%
Lung Squamous Cell Carcinoma 5.99%
Oesophagus Adenocarcinoma 1.24%
Oesophagus Squamous Cell Carcinoma 0.82%
Pancreas Ductal Carcinoma 0.98%

Synthetic Lethal Network

Genes with an experimentally identified or computationally predicted synthetic-lethal relationship to PIK3CG, aggregated across our SSL data sources. Click any partner node to view that gene’s page.

Nodes and edges are coloured by the SSL data source. Partners appearing in more than one source are shown in grey.

BioGRID SLOrth SynLethDB MexDrugs Multi-source
Sources: BioGRID, SLOrth, SynLethDB, MexDrugs

Clinical Trials

Total Trials Found: 2

NCT ID Condition Brief Title Phase Status
NCT00907205 Advanced or Metastatic Solid Tumors, Cancer, Solid Cancers A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid Tumors PHASE1 COMPLETED
NCT00996892 Solid Tumors Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Pictilisib in Patients With Locally Advanced or Metastatic Solid Tumors PHASE1 TERMINATED
NCT04330625 Hyperglycemia Drug Induced Glucagon Receptor Inhibition to Enable Breast Cancer Patients to Benefit From PI3K Inhibitor Therapy (REMD-477) PHASE1 TERMINATED
NCT03696355 Brain and Central Nervous System Tumors Study of GDC-0084 in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma or Diffuse Midline Gliomas PHASE1 COMPLETED
NCT00974584 Non-Squamous Non-Small Cell Lung Cancer A Study of the Safety and Pharmacology Of PI3-Kinase Inhibitor GDC-0941 In Combination With Either Paclitaxel And Carboplatin (With or Without Bevacizumab) or Pemetrexed, Cisplatin, And Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer PHASE1 COMPLETED
NCT01756118 Acute Lymphoblastic Leukemia, Leukemia, Myelocytic, Acute, Chronic Myelogenous Leukemia With Crisis of Blast Cells A Phase I, Dose-finding Study of BEZ235 in Adult Patients With Relapsed or Refractory Acute Leukemia PHASE1 COMPLETED
NCT01343498 Malignant Solid Tumour Study of PI3 Kinase/mTOR Inhibitor BEZ235 Twice Daily for Advanced Solid Tumors PHASE1 COMPLETED
NCT02253420 Medical Oncology COPANLISIB (BAY80-6946) Drug-drug Interaction and Cardiovascular Safety Study in Advanced Solid Tumor and Non-Hodgkin's Lymphoma Patients PHASE1 COMPLETED
NCT00876122 Non-Hodgkin's Lymphoma, Solid Cancers A Study of GDC-0941 in Patients With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable PHASE1 COMPLETED
NCT01540253 Unspecified Adult Solid Tumor, Protocol Specific PI3K Inhibitor BKM120 and Docetaxel in Treating Patients With Advanced Solid Tumor That is Locally Advanced, Cannot Be Removed By Surgery, or Metastatic PHASE1 COMPLETED